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ORIGINAL INVESTIGATION
Triglyceride glucose index is an independent 
predictor for the progression of coronary artery 
calcification in the absence of heavy coronary 
artery calcification at baseline
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Abstract 
Background: Data on the relationship between the triglyceride glucose (TyG) index and coronary artery calcification 
(CAC) progression is limited. This longitudinal study evaluated the association of TyG index with CAC progression in 
asymptomatic adults.
Methods: We enrolled 12,326 asymptomatic Korean adults who had at least two CAC evaluations. The TyG index 
was determined using ln (fasting triglycerides [mg/dL] × fasting glucose [mg/dL]/2). CAC progression was defined as 
a difference ≥ 2.5 between the square roots (√) of the baseline and follow‑up coronary artery calcium score (CACS) 
(Δ√transformed CACS). Annualized Δ√transformed CACS was defined as Δ√transformed CACS divided by the inter‑
scan period.
Results: During a mean 3.3 years, the overall incidence of CAC progression was 30.6%. The incidence of CAC pro‑
gression (group I [lowest]: 22.7% versus [vs.] group II: 31.7% vs. group III [highest]: 37.5%, P < 0.001) and annualized 
Δ√transformed CACS (group I: 0.46 ± 1.44 vs. group II: 0.71 ± 2.02 vs. group III: 0.87 ± 1.75, P < 0.001) were markedly 
elevated with increasing TyG index tertiles. Multivariate linear regression analysis showed that TyG index was associ‑
ated with annualized Δ√transformed CACS (β = 0.066, P = 0.036). In multivariate logistic regression analysis, the TyG 
index was significantly associated with CAC progression in baseline CACS ≤ 100.
Conclusion: The TyG index is an independent predictor of CAC progression, especially in adults without heavy base‑
line CAC.
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Background
Recent epidemiologic study revealed that the num-
ber of people who died from cardiovascular (CV) dis-
ease in 2013 was more than 17.3 million, representing 
an increase from 1990 of 40.8% [1]. The progression of 
atherosclerosis-related CV disease (ASCVD) is strongly 
associated with the risk of CV morbidity and mortal-
ity. Coronary artery calcification (CAC) is an effec-
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outcomes [2–4]. Thus, CV risk is commonly assessed 
by the coronary artery calcium score (CACS), which is 
determined by computed tomography. In addition to 
baseline CACS and conventional CV risk factors, CAC 
progression is known as a powerful predictor of mortality 
[5].
The triglyceride glucose (TyG) index has been sug-
gested as a reliable surrogate marker of insulin resistance 
(IR), which is a substantial risk factor for ASCVD [6–9]. 
Previous studies reported that TyG index is significantly 
associated with an increased risk of developing type 2 
diabetes, hypertension, and adverse CV events [10–14]. 
In addition, several cross-sectional studies identified the 
strong relation between the TyG index and atheroscle-
rosis in different clinical conditions [15–21]. However, 
data on the association of TyG index with CAC change 
in asymptomatic adults is limited. Especially, the sig-
nificance of TyG index on CAC progression based on 
baseline CAC status has not been evaluated in a large 
population. Therefore, in the present study, we evaluated 
the association between the TyG index and CAC pro-
gression in asymptomatic 12,326 Korean adults.
Methods
Study population and design
Data from the Korea Initiatives on Coronary Artery Cal-
cification (KOICA) registry were analysed in the present 
study. Briefly, the KOICA is a retrospective, multicentre, 
and observational registry with single ethnicity in the 
setting of self-referral for asymptomatic subjects who 
underwent general health examination at six healthcare 
centres in South Korea [22]. Overall, 93,707 subjects were 
enrolled in the KOICA registry from December 2012 to 
August 2016. Self-reported medical questionnaires were 
used to obtain information on previous medical history. 
All data were obtained during visits to each healthcare 
centre. Among the 93,707 subjects from this registry, 
12,326 subjects who underwent at least two CAC scan 
examinations with available data on the TyG index and 
diabetic status were finally included in the present study.
Data collection
Information on history of hypertension, diabetes, hyper-
lipidaemia, and smoking status for each subject was 
systematically collected. Weight, height, and blood pres-
sure were measured during the healthcare centre visits. 
Weight and height were measured during the subjects 
wore light clothing without shoes. The body mass index 
was calculated as weight (kg)/height  (m2). Blood pres-
sure of the right arm was measured using an automatic 
manometer after resting for at least more than 5  min. 
All blood samples including total cholesterol, triglyc-
eride, high-density lipoprotein cholesterol (HDL-C), 
low-density lipoprotein cholesterol (LDL-C), creatinine, 
glucose, and glycated haemoglobin A1C (HbA1C) levels 
were obtained after at least 8 h of fasting and analysed. 
All methods were performed in accordance with the rel-
evant guidelines and regulations.
Ethical statement
The appropriate institutional review board committees of 
each centre approved the protocol of present study.
Definitions
Hypertension was defined as systolic blood pres-
sure ≥ 140  mmHg or diastolic blood pres-
sure ≥ 90 mmHg, a previous diagnosis of hypertension, or 
use of anti-hypertensive medication [23]. Hyperlipidae-
mia was defined as a total cholesterol level of ≥ 240 mg/
dL or anti-hyperlipidemic treatment. Diabetes was 
defined as either a fasting glucose level ≥ 126  mg/dL, 
HbA1C level ≥ 6.5%, a referral diagnosis of diabetes, or 
use of anti-diabetic treatment [24]. Current smoking his-
tory was considered present if subjects currently smoked 
or smoked until 1 month before the study. The TyG index 
was determined using ln (triglycerides [mg/dL] × glucose 
[mg/dL]/2). All participants were categorised into three 
groups based on the tertile of the TyG index level.
CACS was measured based on the scoring system, as 
previously described by Agatston et  al. [25]. CAC pro-
gression was defined as a difference ≥ 2.5 between the 
square roots (√) of the baseline and follow-up CACSs 
(Δ√transformed CACS) considering inter-scan variabil-
ity [26]. Annualised Δ√transformed CACS was defined 
as Δ√transformed CACS divided by the inter-scan 
period. All computed tomography (CT) scans used to 
assess CAC were obtained from a > 16-slice multi-detec-
tor CT scanner (GE 64-slice Lightspeed, Siemens 16-slice 
Sensation, Philips Brilliance 256 iCT, and Philips Bril-
liance 40-channel multi-detector CT). All centres per-
formed standard prospective or retrospective methods.
Statistical analysis
Continuous variables are expressed as the mean ± stand-
ard deviation. Categorical variables are presented as 
absolute values and proportions. After checking the 
distribution status of variables, the one-way analysis of 
variance test was used to analyse continuous variables 
and the χ2 or Fisher’s exact test was used to analyse cat-
egorical variables, as appropriate. Multivariate linear 
regression analysis was used for the association of clini-
cal variables with annualized Δ√transformed CACS 
in overall participants. Multivariate logistic regression 
analysis was performed to identify independent predic-
tors for CAC progression according to categorical base-
line CACS. All statistical analyses were performed using 
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the Statistical Package for the Social Sciences version 
19 (SPSS, Chicago, Illinois) and SAS version 9.1.3 (SAS 
Institute Inc., Cary, North Carolina). A P-value < 0.05 was 
considered significant in all analyses.
Results
Baseline characteristics
The mean age of the 12,326 participants (10,382 men, 
84.2%) was 51.7 ± 8.5 years. The prevalence of hyperten-
sion, diabetes, hyperlipidaemia, and current smoking was 
33.5%, 13.8%, 28.0%, and 28.5%, respectively. The ranges 
of the TyG index in stratified groups of I (lowest), II, and 
III (highest) were 6.77–8.40, 8.41–8.91, and 8.92–11.62, 
respectively. Systolic and diastolic blood pressure; body 
mass index (BMI); the levels of total cholesterol, triglyc-
eride, LDL-C, glucose, HbA1C, and creatinine; and the 
prevalence of male sex, hypertension, diabetes, hyperlipi-
daemia, and current smoking significantly increased with 
increasing TyG index tertiles. In contrast, the mean age 
and HDL-C levels significantly decreased with increasing 
tertiles (Table 1).
Baseline and change of CAC 
At baseline, overall prevalence of CACA 0, 1–10, 11–100, 
and > 100 was 56.2%, 13.9%, 19.3%, and 10.6%, respec-
tively. According to the TyG index tertiles, the mean 
CACSs were 36.8 ± 153.9, 50.8 ± 174.4, and 50.0 ± 186.1 
in group I, group II, and group III, respectively. The sig-
nificant difference in the proportion of categorical CACS 
among the three groups was observed (Fig.  1). During 
the mean inter-scan period of 3.3 ± 1.8 years, the overall 
incidence of CAC progression was 30.6%. The incidence 
of CAC progression (group I: 22.7% versus [vs.] group 
II: 31.7% vs. group III: 37.5%, P < 0.001), Δ√transformed 
Table 1 Clinical characteristics of the study cohort
Values are presented as the mean ± standard deviation or number (%)
BMI body mass index, BP blood pressure, HbA1C glycated haemoglobin A1C, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, 
TyG triglyceride glucose
Total (n = 12,326) Tertile of TyG index
I (lowest) (n = 4117)
6.77–8.40
II (n = 4129)
8.41–8.91
III (highest) (n = 4080)
8.92–11.62
P
Age, years 51.7 ± 8.5 51.4 ± 9.0 52.1 ± 8.4 51.6 ± 8.0 < 0.001
Male, n (%) 10,382 (84.2) 2974 (72.2) 3633 (88.0) 3775 (92.5) < 0.001
Systolic BP, mmHg 119.6 ± 15.0 117.1 ± 15.0 119.8 ± 14.9 121.8 ± 14.8 < 0.001
Diastolic BP, mmHg 75.0 ± 10.5 72.9 ± 10.7 75.2 ± 10.2 77.1 ± 10.3 < 0.001
BMI, kg/m2 24.6 ± 2.8 23.5 ± 2.7 24.6 ± 2.6 25.5 ± 2.6 < 0.001
Hypertension, n (%) 4016 (33.5) 1036 (26.2) 1355 (33.8) 1625 (40.8) < 0.001
Diabetes, n (%) 1703 (13.8) 248 (6.0) 490 (11.9) 965 (23.7) < 0.001
Hyperlipidemia, n (%) 3455 (28.0) 726 (17.6) 1102 (26.7) 1627 (39.9) < 0.001
Current smoking, n (%) 3229 (28.5) 747 (19.9) 1086 (28.6) 1396 (37.0) < 0.001
Total cholesterol, mg/dL 197.5 ± 34.0 188.2 ± 31.7 197.5 ± 32.9 206.8 ± 34.9 < 0.001
Triglyceride, mg/dL 141.7 ± 89.4 73.2 ± 17.3 122.6 ± 22.2 230.0 ± 102.2 < 0.001
HDL‑C, mg/dL 53.3 ± 16.0 60.2 ± 16.4 52.7 ± 14.9 47.1 ± 13.6 < 0.001
LDL‑C, mg/dL 122.0 ± 31.7 114.2 ± 29.5 125.5 ± 31.1 126.2 ± 33.1 < 0.001
Glucose, mg/dL 97.8 ± 20.3 89.5 ± 10.7 96.4 ± 14.0 107.6 ± 27.7 < 0.001
HbA1C,  % 5.7 ± 0.7 5.5 ± 0.5 5.6 ± 0.6 5.9 ± 1.0 < 0.001
Creatinine, mg/dL 0.95 ± 0.17 0.92 ± 0.18 0.96 ± 0.16 0.97 ± 0.17 < 0.001
Fig. 1 Comparison of baseline coronary artery calcification according 
to triglyceride glucose index tertiles. CACS coronary artery calcium 
scores
Page 4 of 8Won et al. Cardiovasc Diabetol           (2020) 19:34 
CACS (group I: 1.65 ± 3.95 vs. group II: 2.52 ± 4.85 
vs. group III: 3.09 ± 5.21, P < 0.001), and annualised 
Δ√transformed CACS (group I: 0.46 ± 1.44 vs. group II: 
0.71 ± 2.02 vs. group III: 0.87 ± 1.75, P < 0.001) were ele-
vated with increasing TyG index tertiles (Fig. 2).
TyG index and CAC change in each categorical CACS
The incidence of CAC progression was elevated with 
increasing TyG index tertiles in categorical CACSs of 
0, 1–10, 11–100, and > 100 (CACS 0: 8.6% vs. 13.4% 
vs. 18.1%, P < 0.001; CACS 1–10: 52.3% vs. 57.1% 
vs. 61.2%, P < 0.001; CACS 11–100: 44.3% vs. 51.9% 
vs. 54.2%, P < 0.001; CACS > 100: 46.0% vs. 53.6% vs. 
55.7%, P = 0.020). Annualised Δ√transformed CACS 
was elevated with increasing TyG index tertiles in cat-
egorical CACSs of 0 (0.13 ± 0.48 vs. 0.21 ± 0.56 vs. 
0.29 ± 0.85, P < 0.001), 1–10 (0.89 ± 1.07 vs. 1.06 ± 1.26 
vs. 1.20 ± 1.24, P < 0.001), and 11–100 (1.17 ± 1.87 vs. 
1.54 ± 2.30 vs. 1.64 ± 2.26, P < 0.001), not in CACS > 100 
(0.93 ± 3.51 vs. 1.25 ± 4.44 vs. 1.45 ± 2.93, P = 0.143) 
(Fig. 3).
Association between clinical variables and CAC change
Multivariate linear regression analysis showed that 
age, male sex, hypertension, diabetes, hyperlipidae-
mia, obesity, current smoking, creatinine, TyG index, 
and baseline CACS > 100 were associated with annual-
ized Δ√transformed CACS (All P < 0.05) (Table 2). The 
result of multivariate logistic regression analysis for the 
association between clinical variables and CAC pro-
gression was described in Additional file 1: Table S1.
Fig. 2 Changes of CAC according to TyG index tertiles. CAC coronary 
artery calcification, TyG triglyceride glucose
Fig. 3 Changes of CAC according to the baseline CACS. CAC coronary artery calcification, CACS coronary artery calcium score
Table 2 Association of  clinical variables with  annualized 
Δ√transformed CACS
BMI body mass index, CACS coronary artery calcium score, TyG triglyceride 
glucose
Variables β SE P
Age, pre‑1 year increase 0.032 0.002 < 0.001
Male 0.281 0.055 < 0.001
Hypertension 0.255 0.037 < 0.001
Diabetes 0.334 0.050 < 0.001
Hyperlipidemia 0.168 0.037 < 0.001
Obesity 0.113 0.035 0.001
Current smoking 0.146 0.037 < 0.001
Creatinine, per‑1 mg/dL increase 0.357 0.111 0.001
TyG index, per‑1 increase 0.066 0.031 0.036
Baseline CACS > 100 0.230 0.057 < 0.001
Page 5 of 8Won et al. Cardiovasc Diabetol           (2020) 19:34  
TyG index and the risk of CAC progression according 
to the baseline CACS
With regards to the relation of TyG index with CAC pro-
gression according to the baseline CACS, the TyG index 
(per 1-unit increase) was associated with an increased 
risk of CAC progression in baseline CACSs of 0, 1–10, 
and 11–100 after adjusting for age, male sex, BMI, hyper-
tension, diabetes, hyperlipidaemia, current smoking, and 
serum creatinine level. However, this association of the 
TyG index and CAC progression was not observed in 
the condition with baseline CACS > 100 (Table  3). After 
adjusting for age, male sex, BMI, systolic and diastolic BP, 
the level of total cholesterol, triglyceride, HDL-C, LDL-
C, glucose, and creatinine, and current smoking, the rela-
tion of TyG index and CAC progression was consistent 
(Additional file 2: Table S2).
Discussion
The present study aimed to evaluate longitudinal change 
of CAC related to TyG index after considering baseline 
CAC status in asymptomatic adults. A number of stud-
ies reported that the TyG index was related to the risk 
of developing traditional CV disease and adverse clini-
cal events. Recent cross-sectional data from Brazilian 
Cardioprotective Nutritional Program Trial showed the 
positive association of TyG index with metabolic and 
behavioral risk factors [27]. In the present study, we iden-
tified that the incidence of CAC progression was elevated 
with an increasing TyG index irrespective of baseline 
CACS in this study. A remarkable result was that high 
TyG index was significantly associated with an increased 
risk of CAC progression in subjects who had baseline 
CACS ≤ 100 after adjusting for traditional risk factors.
The homeostatic model assessment of IR (HOMA-IR) 
has been traditionally used to measure IR [28, 29]. How-
ever, it is required to measure insulin levels for calculat-
ing the HOMA-IR. Considering that insulin levels are 
not usually achieved during general health check-up in 
South Korea, calculating the HOMA-IR to estimate IR is 
somewhat inconvenient for this population. A number of 
previous studies identified that the TyG index is closely 
correlated with the HOMA-IR [9, 30]. Moreover, recent 
data reported that the value of the TyG index predicting 
IR was better than that of the HOMA-IR [8, 31]. Based on 
these evidences, TyG index has been considered as a sim-
ple and useful surrogate marker of IR in clinical practice.
Although several cross-sectional studies previously 
reported a significant relationship between the TyG 
index and CAC prevalence, longitudinal data have been 
limited in clinical practice. Recently, Park et al. observed 
that an elevated TyG index was related to an increased 
risk of CAC progression in 1175 subjects [32]; however, 
they evaluated the impact of the TyG index on CAC pro-
gression without consideration of the subjects’ baseline 
CACS. Atherosclerosis-related major CV events com-
monly occur even among subjects with low CV risk bur-
den [33, 34]. The Multi-Ethnic Study of Atherosclerosis 
study suggested that the CACS was a strong predictor of 
adverse clinical outcomes and provided clinical informa-
tion beyond traditional CV risk factors [4]. In particular, 
Blaha et  al. reported excellent prognosis in the absence 
of CAC in 44,052 consecutive asymptomatic subjects 
during a mean follow-up of 5.6 ± 2.6 years [35]. Consid-
ering the incremental impact of CAC progression on an 
adverse clinical outcome [5], it is a substantial issue to 
identify independent predictors for CAC progression in 
clinical practice.
In the current study, CAC progression was observed in 
13.0% of participants without CAC at baseline. Impor-
tantly, we found that a high TyG index has a strong asso-
ciation with an increased risk of CAC progression in this 
population after adjusting for confounding clinical fac-
tors. This relation of the TyG index with CAC progres-
sion was consistent in the baseline conditions of CACS 
of 1–10 and 11–100. However, there was no significant 
impact of the TyG index on CAC progression in par-
ticipants with baseline CACS > 100. This result might be 
affected by the relatively small sample size of participants 
with CACS > 100, which was about 10.6% in our study. 
Thus, the significance of the TyG index for predicting 
CAC progression is still uncertain in individuals with 
heavy calcification at baseline. Further prospective stud-
ies with a large sample size are necessary to confirm this 
issue.
Table 3 Impact of  the  TyG index (per 1-unit increase) 
on CAC progression based on baseline categorical CACS
Models: 1 = unadjusted; 2 = adjusted for age, male sex, BMI, hypertension, 
diabetes, hypercholesterolemia, current smoking, and serum creatinine level
BMI body mass index, CAC coronary artery calcification, CACS coronary artery 
calcium score, CI confidence interval, OR odds ratio, RR relative risk, TyG 
triglyceride glucose
OR (95% CI) P RR (95% CI) P
CACS 0
 Model 1 1.83 (1.63–2.05) < 0.001 1.67 (1.52–1.82) < 0.001
 Model 2 1.37 (1.18–1.59) < 0.001 1.30 (1.15–1.46) < 0.001
CACS 1–10
 Model 1 1.39 (1.17–1.65) < 0.001 1.15 (1.07–1.23) < 0.001
 Model 2 1.28 (1.05–1.57) 0.016 1.11 (1.02–1.20) 0.014
CACS 11–100
 Model 1 1.42 (1.24–1.64) < 0.001 1.18 (1.11–1.26) < 0.001
 Model 2 1.34 (1.14–1.59) 0.001 1.15 (1.06–1.24) < 0.001
CACS > 100
 Model 1 1.33 (1.09–1.62) 0.004 1.14 (1.04–1.24) 0.003
 Model 2 1.04 (0.83–1.31) 0.743 1.02 (0.92–1.14) 0.702
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The mechanism underlying the relationship of the TyG 
index with atherosclerosis is unclear. However, previous 
studies revealed the pivotal role of IR in atherosclerosis 
progression via promoting apoptosis of macrophages, 
endothelial cells, and vascular smooth muscle cells [36–
38]. Recently, data from Coronary Artery Risk Develop-
ment in Young Adults (CARDIA) study revealed that 
transitions in metabolic risk occurred early in life and 
metabolic dysfunction is related to subclinical cardiovas-
cular phenotypes including CAC and myocardial hyper-
trophy and dysfunction [39]. Park et  al. suggested that 
TyG index was an effective marker for early detecting 
subclinical coronary atherosclerosis even in the absence 
of traditional CV risk factors [40]. However, considering 
the inconsistent results for the association of metabolic 
syndrome with ASCVD in diabetic patients [41, 42], fur-
ther large prospective investigation for the clinical sig-
nificance of TyG index in established diabetes should be 
necessary in diverse ethnic population.
There are some limitations to the present study. First, 
the KOICA registry was based on a relatively healthy 
population who underwent health check-ups in health-
care centres. The present study only included subjects 
who experienced at least two CAC scan examinations 
with available data on the TyG index and diabetic sta-
tus from the KOICA registry. Thus, this study could not 
represent the characteristics of overall participants of 
KOICA registry and a potential selection bias might be 
present. Second, this was a retrospective study, which 
may be affected by unidentified confounders. Third, we 
only evaluated the association between the baseline TyG 
index and CAC progression; however, the mean change 
of the TyG index was very small: − 0.02 ± 0.48. Longitu-
dinal consecutive changes of the TyG index during fol-
low-up could not be confirmed. Fourth, the homeostatic 
model assessment of IR was not analysed because insulin 
levels were not measured in the KOICA registry. Fifth, 
some important data including physical activity, alcohol 
consumption, family history of disease were unavailable. 
Sixth, we could not control the effect of medications for 
hypertension, diabetes, and hyperlipidaemia on CAC 
progression because of the observational study design. 
Finally, the present study included only the Korean popu-
lation. However, this study is unique in that we identified 
the predictive value of the TyG index for CAC progres-
sion according to the baseline CAC status in a large sam-
ple of asymptomatic adults.
Conclusion
The TyG index is strongly associated with CAC progres-
sion after adjusting for confounding clinical variables, 
especially in adults without heavy CAC at baseline.
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